메뉴 건너뛰기




Volumn 32, Issue 6, 2010, Pages e241-e243

Successful treatment of late, recurrent wilms tumor with high-dose chemotherapy and autologous stem cell rescue in third complete response

Author keywords

Autologous stem cell transplant; High dose chemotherapy; Relapse; Wilms tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE; MELPHALAN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; IFOSFAMIDE; INTERLEUKIN 11; TOPOTECAN; VINCRISTINE;

EID: 77955860704     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181e5e25b     Document Type: Article
Times cited : (13)

References (15)
  • 1
    • 31444446505 scopus 로고    scopus 로고
    • Current therapy for Wilms’ tumor
    • Dome JS, Metzger ML. Current therapy for Wilms’ tumor. The Oncologist. 2005; 10: 815-826.
    • (2005) The Oncologist. , vol.10 , pp. 815-826
    • Dome, J.S.1    Metzger, M.L.2
  • 2
    • 4344642234 scopus 로고    scopus 로고
    • Treatment of relapsed Wilms’ tumor with high dose therapy and autologous hematopoietic stem cell rescue: The experience at Children’s Memorial Hospital
    • Campbell A, Cohn S, Reynolds M, et al. Treatment of relapsed Wilms’ tumor with high dose therapy and autologous hematopoietic stem cell rescue: the experience at Children’s Memorial Hospital. J Clin Oncol. 2004; 22: 2885-2890.
    • (2004) J Clin Oncol. , vol.22 , pp. 2885-2890
    • Campbell, A.1    Cohn, S.2    Reynolds, M.3
  • 3
    • 0021888070 scopus 로고
    • Recurrence of Wilms’ tumor after apparent cure
    • Kim TH, Zaatari G, Baum ES, et al. Recurrence of Wilms’ tumor after apparent cure. J Pediatr. 1985; 107: 44-49.
    • (1985) J Pediatr. , vol.107 , pp. 44-49
    • Kim, T.H.1    Zaatari, G.2    Baum, E.S.3
  • 4
    • 37549055839 scopus 로고    scopus 로고
    • Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group
    • Malogolowkin M, Cotton CA, Green DM, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer. 2008; 50: 236-241.
    • (2008) Pediatr Blood Cancer. , vol.50 , pp. 236-241
    • Malogolowkin, M.1    Cotton, C.A.2    Green, D.M.3
  • 7
    • 0000498670 scopus 로고
    • Wilms’ tumor: Its behavior and prognosis
    • Collins VP. Wilms’ tumor: its behavior and prognosis. J La State Med Soc. 1955; 107: 474-480.
    • (1955) J La State Med Soc. , vol.107 , pp. 474-480
    • Collins, V.P.1
  • 8
    • 28844480519 scopus 로고    scopus 로고
    • Collins’ law revisited: Can we reliably predict the time to recurrence in common pediatric tumors?
    • Paulino AC. Collins’ law revisited: can we reliably predict the time to recurrence in common pediatric tumors? Pediatr Hematol Oncol. 2006; 23: 81-86.
    • (2006) Pediatr Hematol Oncol. , vol.23 , pp. 81-86
    • Paulino, A.C.1
  • 9
    • 0024602789 scopus 로고
    • Prognostic factors for children with recurrent Wilms’ tumor: Results from the second and third National Wilms’ tumor study
    • Grundy P, Breslow N, Green DM, et al. Prognostic factors for children with recurrent Wilms’ tumor: results from the second and third National Wilms’ tumor study. J Clin Oncol. 1989; 7: 638-647.
    • (1989) J Clin Oncol. , vol.7 , pp. 638-647
    • Grundy, P.1    Breslow, N.2    Green, D.M.3
  • 10
    • 31444451325 scopus 로고    scopus 로고
    • Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms’ tumor: A report from the National Wilms’ tumor study group
    • Grundy P, Breslow N, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms’ tumor: a report from the National Wilms’ tumor study group. J Clin Oncol. 2005; 23: 7312-7321.
    • (2005) J Clin Oncol. , vol.23 , pp. 7312-7321
    • Grundy, P.1    Breslow, N.2    Li, S.3
  • 11
    • 0031725726 scopus 로고    scopus 로고
    • High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high risk recurrent Wilms’ tumor: A French Society of Pediatric Oncology Study
    • Pein F, Michon J, Valteau-Couanet V, et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high risk recurrent Wilms’ tumor: a French Society of Pediatric Oncology Study. J Clin Oncol. 1998; 16: 3295-3301.
    • (1998) J Clin Oncol. , vol.16 , pp. 3295-3301
    • Pein, F.1    Michon, J.2    Valteau-Couanet, V.3
  • 12
    • 0036018913 scopus 로고    scopus 로고
    • Ifosfamide, carboplatin, and etoposide in children with poor-risk relapsed Wilms’ Tumor: A Children’s Cancer Group report
    • Abu-Gosh AM, Krailo MD, Goldman SC, et al. Ifosfamide, carboplatin, and etoposide in children with poor-risk relapsed Wilms’ Tumor: a Children’s Cancer Group report. Ann Oncol. 2002; 13: 460-469.
    • (2002) Ann Oncol. , vol.13 , pp. 460-469
    • Abu-Gosh, A.M.1    Krailo, M.D.2    Goldman, S.C.3
  • 13
    • 0036952620 scopus 로고    scopus 로고
    • Nephroblastoma high dose chemotherapy with autologous stem cell rescue in children with nephroblastoma
    • Kremens B, Gruhn B, Klingebiel T, et al. Nephroblastoma high dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transplant. 2002; 30: 893-898.
    • (2002) Bone Marrow Transplant. , vol.30 , pp. 893-898
    • Kremens, B.1    Gruhn, B.2    Klingebiel, T.3
  • 14
    • 44149083336 scopus 로고    scopus 로고
    • Treatment of high-risk relapsed Wilms’ tumor with dose intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell support: Experience by the Italian Association of Pediatric Hematology and Oncology
    • Spreafico F, Bisogno G, Collini P, et al. Treatment of high-risk relapsed Wilms’ tumor with dose intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell support: experience by the Italian Association of Pediatric Hematology and Oncology. Pediatr Blood Cancer. 2008; 51: 23-28.
    • (2008) Pediatr Blood Cancer. , vol.51 , pp. 23-28
    • Spreafico, F.1    Bisogno, G.2    Collini, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.